41
Participants
Start Date
November 11, 2024
Primary Completion Date
November 5, 2027
Study Completion Date
April 21, 2028
PGDM1400LS
IV Antibody Infusion based on subject's weight
VRC07-523LS
IV Antibody Infusion based on subject's weight
PGT121.414.LS
IV Antibody Infusion based on subject's weight
ART Regimen prior to enrolling in Step 1a
Antiviral drugs are not study product. However, participants will continue to receive the ART regimen they were receiving prior to enrolling in the study during Step 1a.
ART Regimen prior to enrolling in Step 1b
Antiviral drugs are not study product. However, participants will continue to receive the ART regimen they were receiving prior to enrolling in the study during Step 1b.
Analytic Treatment Interruption
(all anti-HIV agents are discontinued)
RECRUITING
Francistown CRS (CRS #31891), Francistown
RECRUITING
Botswana Harvard Health Partnership CRS (CRS #31833), Gaborone
National Institute of Allergy and Infectious Diseases (NIAID)
NIH